|
gptkbp:instanceOf
|
gptkb:drug
benzodiazepine
|
|
gptkbp:antidote
|
gptkb:flumazenil
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
N05CD07
|
|
gptkbp:brand
|
gptkb:Restoril
|
|
gptkbp:CASNumber
|
846-50-4
|
|
gptkbp:chemicalFormula
|
C16H13ClN2O2
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
pregnancy
severe respiratory insufficiency
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:discoveredBy
|
gptkb:Milan_Hašek
|
|
gptkbp:discoveredIn
|
1960s
|
|
gptkbp:eliminationHalfLife
|
8-20 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasInChIKey
|
IMJSJBOJVJBQCG-UHFFFAOYSA-N
|
|
gptkbp:hasSMILES
|
CN1C(=O)CN=C(C2=CC=CC=C2Cl)C1=O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
temazepam
|
|
gptkbp:interactsWith
|
gptkb:beer
opioids
other CNS depressants
|
|
gptkbp:IUPACName
|
gptkb:7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one_3-oxide
|
|
gptkbp:legalStatus
|
gptkb:Class_C_(UK)
gptkb:Schedule_3_(Australia)
prescription only
List 1 (Canada)
|
|
gptkbp:marketedAs
|
1969
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor positive allosteric modulator
|
|
gptkbp:meltingPoint
|
163-164°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
300.74 g/mol
|
|
gptkbp:overdoseSymptoms
|
coma
respiratory depression
excessive sedation
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
gptkb:D_(Australia)
|
|
gptkbp:producedBy
|
gptkb:Mallinckrodt_Pharmaceuticals
gptkb:Mylan
gptkb:Teva_Pharmaceuticals
|
|
gptkbp:PubChem_CID
|
5391
|
|
gptkbp:riskFactor
|
dependence
withdrawal symptoms
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:center
dizziness
fatigue
headache
drowsiness
impaired coordination
|
|
gptkbp:UNII
|
CHB49086LJ
|
|
gptkbp:usedFor
|
sleep disorders
insomnia
|
|
gptkbp:bfsParent
|
gptkb:benzodiazepines
gptkb:benzodiazepine
|
|
gptkbp:bfsLayer
|
6
|